Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | The EPOCH-R clinical trial in Burkitt lymphoma

Jeremy Abramson • 4 Dec 2015
ASH 2015
B-Cell Lymphoma

Jeremy Abramson, MD, from the Massachusetts General Hospital, Massachusetts, MA gives an overview of the preliminary data being presented at the American Society of Hematology (ASH) 2015 Annual Meeting in Orlando, FL, on the results of the multi-center prospective Phase II study of Dose-Adjusted EPOCH-R for Burkitt Lymphoma.

More from Jeremy Abramson

2:52
Current immunotherapeutic approaches in DLBCL: the value of CAR-T cells and bispecific antibodies
Jeremy Abramson • 12 Dec 2022
2:05
Emerging treatment strategies for patients with high-risk follicular lymphoma
Jeremy Abramson • 12 Dec 2022
3:23
Brentuximab vedotin, nivolumab, doxorubicin & dacarbazine for early stage classical Hodgkin lymphoma
Jeremy Abramson • 12 Dec 2022
2:46
TRANSFORM: liso-cel versus standard of care as second-line therapy for R/R LBCL
Jeremy Abramson • 12 Dec 2022

Related Videos

1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals